Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04832659 · ClinicalTrials.gov registry record · NA
Assessment of Biomarkers in Children to Help Parents Quit Tobacco
A NA study of Tobacco Dependence, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- NA
- Development phase
- 865
- Enrollment target
- 1
- Study location
NCT04832659: Active NA study of Tobacco Dependence, sponsored by Massachusetts General Hospital.
NCT04832659 is a NA study of Tobacco Dependence that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 865 participants, above the 448-participant average among 28 other Tobacco Dependence trials with a reported enrollment target (93% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04832659, a NA study of Tobacco Dependence, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 865 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized controlled trial will test whether adding biomarker measurement and informed outreach for tobacco smoke exposure as part of routine practice increases identification and improves treatment, effectiveness, and sustainability of a parental tobacco control intervention that will be integrated into pediatric practice.
Primary Outcome
Parental 7-day point-prevalence tobacco abstinence at 12-month follow-up, biochemically confirmed (corrected for NRT use)
Conditions Studied
Interventions
- BEHAVIORAL CEASE
- BEHAVIORAL CEASE + BIO
Study Locations (1)
Ohio
- MetroHealth System - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 865 participants |
| Start Date | 2023-01-20 |
| Est. Completion | 2026-02-28 |
| Phase | NA |
What the registry record for NCT04832659 still lists
NCT04832659 is an interventional study that assigns participants to a tested intervention. The registered 865 participants enrollment target is mid-sized for trials with a published cap, above the 448-participant average among 28 other Tobacco Dependence trials with a reported enrollment target (93% higher).
The record links to 1 condition, with Tobacco Dependence appearing as the primary indexed condition, and to 2 interventions - of which CEASE is the first listed.
NCT04832659 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04832659 about?
NCT04832659 is a clinical study titled "Assessment of Biomarkers in Children to Help Parents Quit Tobacco". This randomized controlled trial will test whether adding biomarker measurement and informed outreach for tobacco smoke exposure as part of routine practice increases identification and improves treatment, effectiveness, and sustainability of a parental tobacco control intervention that will be inte...
What is the current status of trial NCT04832659?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 865 participants. The study started on 2023-01-20. Estimated completion is 2026-02-28.
What conditions does trial NCT04832659 study?
This clinical trial studies the following conditions: Tobacco Dependence.
What interventions are being tested in trial NCT04832659?
The interventions under investigation include: CEASE (BEHAVIORAL), CEASE + BIO (BEHAVIORAL).
Who is sponsoring clinical trial NCT04832659?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04832659 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04832659's enrollment target sits among peer trials
865 5th of 28 higher than 24 of 28 other Tobacco Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Harm Reduction for Smokers With Mental Illness
RECRUITING · NA
-
Reach Through Equitable Implementation in Utah
RECRUITING · NA
-
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
RECRUITING · NA
-
Use of Nicotine Pouches Among Daily Smokers
RECRUITING · NA
-
Smoke-free Home Study in Subsidized Housing
RECRUITING · NA
-
Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05369052 · 865 participants · Phase 3
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
- NCT06256588 · 864 participants · Phase 3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- NCT06527794 · 864 participants · NA
Remote Hypertension Management for Black Patients
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI